Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 04, 2026
Billionaires Are Gobbling Up These 3 Healthcare Stocks
08:13pm, Saturday, 11'th Apr 2020
These three developmental-stage pharma stocks are attracting some of the smartest investors right now.
3 High-Growth Stocks That Could Soar
11:09am, Friday, 10'th Apr 2020
The coronavirus may have temporarily slowed them down, but some businesses are built better than others to shrug off the COVID-19 contagion.
Harbour Capital Advisors LLC Boosts Stake in EXACT Sciences Co. (NASDAQ:EXAS)
10:16am, Thursday, 09'th Apr 2020
Harbour Capital Advisors LLC grew its stake in EXACT Sciences Co. (NASDAQ:EXAS) by 33.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Excha
Why 'Kimtirement' is a real thing with this longtime biotech exec
09:51pm, Wednesday, 08'th Apr 2020
After her company completed a merger in November, people told Kim Popovits to take six months off before considering anything.
Exact Sciences schedules first-quarter 2020 earnings call
10:00am, Wednesday, 08'th Apr 2020
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company plans to release its first-quarter 2020 financial results after the close of the U.S. financial markets on May 6, 2020. Following t
AQR Capital Management LLC Sells 8,492 Shares of EXACT Sciences Co. (NASDAQ:EXAS)
09:46am, Tuesday, 07'th Apr 2020
AQR Capital Management LLC reduced its position in EXACT Sciences Co. (NASDAQ:EXAS) by 34.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 15,968 shares of the
EXACT Sciences Co. (NASDAQ:EXAS) Insider Mark Stenhouse Sells 11,948 Shares of Stock
08:14am, Tuesday, 07'th Apr 2020
EXACT Sciences Co. (NASDAQ:EXAS) insider Mark Stenhouse sold 11,948 shares of the firm’s stock in a transaction that occurred on Friday, April 3rd. The stock was sold at an average price of $56.69,
Quadrant Capital Group LLC Sells 315 Shares of EXACT Sciences Co. (NASDAQ:EXAS)
11:44am, Monday, 06'th Apr 2020
Quadrant Capital Group LLC reduced its stake in EXACT Sciences Co. (NASDAQ:EXAS) by 26.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission
Stifel Nicolaus Cuts EXACT Sciences (NASDAQ:EXAS) Price Target to $90.00
10:00am, Monday, 06'th Apr 2020
EXACT Sciences (NASDAQ:EXAS) had its price objective decreased by Stifel Nicolaus from $110.00 to $90.00 in a research report sent to investors on Thursday morning, BenzingaRatingsTable reports. Stife
EXACT Sciences Co. (NASDAQ:EXAS) Shares Sold by Cubist Systematic Strategies LLC
09:54am, Sunday, 05'th Apr 2020
Cubist Systematic Strategies LLC lessened its holdings in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 12.3% in the fourth quarter, according to the company in its most recent filing with the SEC. Th
Equities Analysts Set Expectations for EXACT Sciences Co.'s Q1 2020 Earnings (NASDAQ:EXAS)
05:44am, Friday, 03'rd Apr 2020
EXACT Sciences Co. (NASDAQ:EXAS) – Analysts at SVB Leerink raised their Q1 2020 earnings estimates for EXACT Sciences in a research report issued to clients and investors on Monday, March 30th. SVB
PPD (NASDAQ:PPD) & EXACT Sciences (NASDAQ:EXAS) Head to Head Contrast
05:26am, Friday, 03'rd Apr 2020
PPD (NASDAQ:PPD) and EXACT Sciences (NASDAQ:EXAS) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst reco
Exact Sciences: Well Positioned To Execute In FY20
06:33pm, Thursday, 02'nd Apr 2020
Dominance in colon cancer testing to continue. Acquired company Genomic Health's broad service portfolio to see full impact in FY20. Investments made in sales r
10x Genomics Appoints Kim Popovits to Board of Directors
01:00pm, Thursday, 02'nd Apr 2020
PLEASANTON, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (TXG) today announced the appointment of Kim Popovits, former Chairman of the Board, President and Chief Executive Officer o
10x Genomics Appoints Kim Popovits to Board of Directors
01:00pm, Thursday, 02'nd Apr 2020
Former Genomic Health CEO brings decades of healthcare experience to Board
